A picture containing text, clipart

Description automatically generated

   

October 29, 2021

 

VIA EDGAR  

 

United States Securities and Exchange Commission
Division of Corporation Finance

100 F Street, N.E.
Washington, D.C. 20549

  

  Re:

Synthetic Biologics, Inc.

Registration Statement on Form S-3

File No: 333-260449

Request For Acceleration

 

Ladies and Gentlemen:

 

Synthetic Biologics, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-260449), to become effective on Tuesday, November 2, 2021, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

 

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. or Patrick J. Egan, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at (914) 557-5574 or (212) 907-6457 with any questions you may have concerning this request, and please notify her or him when this request for acceleration has been granted.

 

  Very truly yours,
   
  Synthetic Biologics, Inc.
   
  By:  /s/ Steven A. Shallcross
    Name: Steven A. Shallcross
    Title: Chief Executive Officer and Chief Financial Officer

 

 

 cc:

Leslie Marlow, Esq., Gracin & Marlow, LLP  

Patrick J. Egan, Esq., Gracin & Marlow, LLP